- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Wayne Winegarden, PhD, on Downside of Importing Drugs From Canada
We sat down with Wayne Winegarden, PhD, a senior fellow in business and economics at the Pacific Research Institute (PRI) and director of PRI's Center for Medical Economics and Innovation, to discuss why the FDA’s implementation of the Safe Importation Action Plan is controversial.
Earlier this year, President Trump signed 4 executive orders designed to lower the cost of prescription drugs. One of those orders allows for insulins and other medications, such as biologics, to be imported from countries like Canada, where the same products sold in the United States are sold at lower prices. Since the signing, the FDA has officially adopted a final rule to implement the plans.
The rule, dubbed as the Safe Importation Action Plan, permits states and indigenous tribes as well as some pharmacies and wholesalers permission to submit importation program proposals to the FDA for review and authorization. Although HHS and federal officials believe the plan has real potential to lower costs, some experts see the plan as both ineffective and possibly dangerous.
We sat down with Wayne Winegarden, PhD, a senior fellow in business and economics at the Pacific Research Institute (PRI) and director of PRI's Center for Medical Economics and Innovation, to discuss why this plan is so controversial and what steps should be taken instead to help lower drug costs.
To read more on Wayne’s thoughts of this plan, click here.
To learn more about the Safe Importation Action Plan, click here.
To learn more about President Trump’s executive orders, click here.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
